Spark therapeutics, inc. (ONCE)
Income statement / Quarterly
Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Revenue from Contract with Customer, Excluding Assessed Tax

22,447

13,503

20,771

13,157

10,707

25,185

15,676

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Total revenues

-

-

-

-

-

-

-

-

1,900

1,483

1,274

-

1,302

1,288

1,288

17,197

1,302

1,288

2,274

613

0

0

20

Operating expenses:
Cost of goods sold

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

44,655

42,244

35,831

36,792

32,829

25,524

30,109

30,095

39,341

32,989

32,735

26,122

22,384

19,621

18,251

16,554

11,796

9,343

8,334

6,181

4,652

2,129

3,387

Acquired in-process research and development

-

-

-

-

-

-

-

-

1,750

3,070

-

-

0

0

-

-

-

-

-

-

-

-

-

Impairment of acquired in-process research and development

-

-

-

-

-

-

-

-

0

15,696

-

-

0

0

-

-

-

-

-

-

-

-

-

Selling, general and administrative

41,407

36,407

38,291

32,352

29,305

29,749

33,489

36,341

26,641

26,729

21,413

16,469

12,049

10,676

8,873

6,872

6,461

6,333

3,684

2,701

2,106

2,038

1,016

Total operating expenses

91,105

79,948

77,617

71,540

62,452

59,784

64,588

70,220

67,732

78,484

54,148

53,723

34,434

30,298

27,125

23,427

18,258

15,677

12,018

9,632

6,758

4,168

4,403

Loss from operations

-68,658

-66,445

-56,846

-58,383

-51,745

-34,599

-48,912

-62,811

-65,832

-77,001

-52,874

-37,420

-33,131

-29,009

-25,837

-6,229

-16,955

-14,388

-9,744

-9,019

-6,758

-4,168

-4,383

Equity Securities, FV-NI, Unrealized Gain (Loss)

-13

-422

-211

-9,369

1,672

2,255

364

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Interest income, net

2,095

2,670

2,702

2,574

2,714

2,521

2,185

1,844

1,112

532

585

583

568

333

260

74

54

51

11

-

2

0

-

Other income

0

0

-

-

0

110,000

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss before income taxes

-66,576

-64,197

-54,355

-65,178

-47,359

80,177

-46,363

-60,967

-64,720

-76,469

-52,289

-

-32,562

-28,676

-

-

-

-

-

-

-

-

-

Income tax benefit (expense)

26

33

3

79

-2

12

10

854

292

-2,109

0

-

0

0

-

-

-

-

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

Net Income (Loss) Attributable to Parent

-66,602

-64,230

-54,358

-65,257

-47,357

80,165

-46,373

-61,821

-65,012

-74,360

-52,289

-36,837

-32,562

-28,676

-25,576

-6,154

-16,900

-14,336

-9,733

-9,015

-6,756

-4,168

-4,383

Preferred stock dividends

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

634

-

0

0

-

Basic and diluted net loss per common share (in dollars per share)

-1.72

-

-1.43

-

-1.26

-

-1.25

-

-1.90

-

-1.70

-1.23

-1.07

-1.04

-0.95

-0.22

-0.70

-0.60

-0.58

-1.77

-1.22

-0.79

-0.86

Weighted average basic and diluted common shares outstanding (in shares)

38,747

-

37,906

-

37,498

-

37,046

-

34,258

-

30,771

30,583

30,368

27,456

26,807

24,696

24,138

24,080

17,925

5,712

5,531

5,246

5,100

Basic net income (loss) per common share (in usd per share)

-

-1.66

-

-

-

2.15

-

-

-

-2.40

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted net income (loss) per common share (in usd per share)

-

-1.66

-

-

-

2.07

-

-

-

-2.40

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted Average Number of Shares Outstanding, Basic

-

38,686

-

-

-

37,254

-

-

-

30,968

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted Average Number of Shares Outstanding, Diluted

-

38,686

-

-

-

38,702

-

-

-

30,968

-

-

-

-

-

-

-

-

-

-

-

-

-

Net Income (Loss) Attributable to Parent

-66,602

-64,230

-54,358

-65,257

-47,357

80,165

-46,373

-

-65,012

-74,360

-

-

-

-

-

-6,154

-16,900

-14,336

-10,368

-9,722

-6,756

-4,168

-4,383

Other comprehensive income (loss):
Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax

-210

528

854

-28

308

470

-164

-6,147

-359

1,644

-301

-857

126

-70

0

-

0

0

-

-

-

-

-

Unrealized gain (loss) on interest rate swap

-265

-631

-373

-763

122

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Foreign exchange translation adjustment

-115

-64

45

-34

-12

-58

21

1,275

60

-697

-595

9

1

-3

0

-

0

0

-

-

-

-

-

Total comprehensive loss

-67,192

-64,397

-53,832

-66,082

-46,939

80,577

-46,516

-67,967

-65,431

-72,019

-53,185

-37,577

-32,690

-28,601

-25,576

-

-16,900

-14,336

-

-

-

-

-

Product sales, net
Revenue from Contract with Customer, Excluding Assessed Tax

6,918

11,460

9,782

11,374

8,866

4,314

2,419

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Cost of goods sold

1,010

1,297

745

300

318

269

121

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Contract revenue
Revenue from Contract with Customer, Excluding Assessed Tax

15,529

2,043

10,989

1,783

1,841

20,871

13,257

7,409

1,900

1,483

1,274

-

-

-

-

-

-

-

-

-

-

-

-

Cost of goods sold

4,033

0

2,750

1,796

0

4,242

869

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-